- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of October 9
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of October 9.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 9.
Number 5: A growing number of physicians and patient groups are voicing concern over step therapy, or “fail first” policies, which can make it more difficult for patients to receive biologic and biosimilar therapies.
Number 4: A recent study provided much-needed data on the use of biosimilar infliximab in children with inflammatory bowel disease.
Number 3: Contributors George Yu and Christopher Bruno of Schiff Hardin discuss the recent decision in the case of Amgen v Hospira and its implications for safe harbor in biosimilar development.
Number 2: Contributor Sonia T. Oskouei addresses the question of what the United States can learn from the European experience with biosimilars.
Finally, Number 1: The FDA has issued Mylan and Biocon a Complete Response Letter for their proposed pegfilgrastim biosimilar, referenced on Neulasta.
To read all of these articles and more, visit centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
FDA Approves Another Pair of Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for osteoporosis, bone metastases, and other bone-related conditions, amidst a flurry of similar approvals and legal settlements.
